ArticleJournal of neurology2026
Recanalization therapy in stroke patients with malignancies: in-hospital outcomes by cancer subtype in a nationwide administrative data analysis.
Article in Journal of neurology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveStroke is a common risk among patients with cancer, and the odds of a fatal stroke are estimated to be twice those of the general population. Due to the exclusion of cancer patients from major intravenous thrombolysis and thrombectomy trials, existing literature consists largely of small case series lacking sufficient statistical power. We aimed to evaluate the safety profile of acute stroke therapies in patients with active cancer, stratified by cancer localization, using a nationwide administrative dataset.
methodsThis retrospective, large-scale cohort study utilized data from the German Federal Statistical Office (DESTATIS). We analyzed all inpatient cases of acute ischemic stroke receiving recanalization therapy (intravenous thrombolysis and endovascular thrombectomy) in Germany. The primary endpoints were in-hospital mortality and safety outcomes (intracranial bleeding, subarachnoid hemorrhage, and acute anemia). To control for baseline characteristics, adjusted odds ratios (aOR) were calculated using multivariable logistic regression.
resultsWe analyzed 154,333 patients receiving intravenous thrombolysis (2482 with and 151,851 without cancer) and 39,534 receiving endovascular thrombectomy (1580 with and 37,954 without cancer). In the thrombolysis cohort, patients with cancer had significantly higher rates of in-hospital death (10.88% vs. 6.26%; OR 1.83; p < 0.001) and intracranial bleeding (5.76% vs. 4.58%; OR 1.27; p = 0.005). Similarly, in the thrombectomy cohort, active cancer was associated with increased in-hospital mortality (28.10% vs. 20.00%; OR 1.56; p < 0.001) and subarachnoid hemorrhage (6.14% vs. 4.67%; OR 1.33; p = 0.007). After multivariable adjustment, stratification revealed highly heterogeneous complication profiles depending heavily on the specific cancer subtype.
conclusionsThis large-scale analysis demonstrates that while mortality and specific bleeding risks are generally elevated in stroke patients with malignancies, these risks depend strongly on the cancer subtype. These findings advocate for a tailored, risk-based approach to recanalization therapy, weighing individual complication profiles rather than a general exclusion of patients with cancer from acute stroke therapies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.